<-  All posts

MedTech Actuator accepts Diag-Nose, fast tracking innovation

Updated: 12/02/2026 | Read time: 2 mins

What’s the big deal about getting into MedTech Actuator?

It’s a truly impressive team effort.

It goes without saying that acceptance into the MedTech Actuator marks a major milestone for Diag-Nose - a testament to the team’s dedication, focus, and sacrifice.

Now, following graduation from Perth Biodesign and a 6 month relocation to Melbourne, Victoria just to participate, CEO Eldin Rostom has helped the company to receive it’s biggest pre-seed round yet.

And this comes hot on the heels of being a finalist in Medtech’s Got Talent.

Safe to say, Diag-Nose is on fire.

‍

MedTech Actuator - turning MedTech dreams into commercial reality

MedTech Actuator isn’t just another program.

It has helped over 1,000 startups accelerate healthcare innovation, engaged more than 70 industry partners, and generated $6 billion in market value across its portfolio.

The program’s impact on the workforce is equally impressive, with over 5,000 clinicians and researchers trained to thrive in industry.

And now, Diag-Nose is part of this startup-scaling powerhouse.

Mic drop.

‍

The difference the program will make for the company both now and in the future

Eldin and the team will participate in a huge 15-month intensive program, which will see technology development combined with entrepreneurial skill-building.

Beyond the unbelievable $200,000 investment, the program offers a fast-track to the first major round of venture capital investment through partners Artesian Venture Capital. Additionally, we will gain access to an extraordinary new network of mentors, business coaches, and industry experts to support us in our efforts.

“Having access to the Medtech Actuator program is a fantastic opportunity – it really takes a village to be able to grow a start-up and the program brings the village to you by surrounding the companies with mentors, business coaches and expert suppliers with a demonstrated track record in MedTech. This will allow Diag-Nose to continue validating our market and developing our product as well as gain access to potential future investors.” said Eldin.

With this support, Diag-Nose is set to advance its mission of reducing unnecessary antibiotic use and improving patient outcomes across Australia and beyond.

Keep an eye out for our latest breakthrough and behind-the scenes updates by following us on LinkedIn!

‍

About Diag-Nose.io

Diag-Nose.io, founded in 2020, is a TechBio company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions.

Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies.

The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.

Learn more at Diag-Nose.io

About MedTech Actuator

Founded in 2018, MedTech Actuator is Asia Pacific’s leading MedTech commercialisation program, dedicated to transforming health-based startups into global companies that deliver real-world impact.

The initiative connects founders, researchers, and investors, accelerating innovations that improve lives while driving economic growth. At its core, MedTech Actuator focuses on building capability - not just knowledge - empowering entrepreneurs with the skills, networks, and confidence to bring human-centred solutions to market.

United by a passion for innovation with tangible human impact, MedTech Actuator nurtures the next generation of healthtech leaders and breakthrough medical technologies.

Learn more at MedTech Actuator

‍

Updated: 12/02/2026 | Read time: 2 mins

What’s the big deal about getting into MedTech Actuator?

It’s a truly impressive team effort.

It goes without saying that acceptance into the MedTech Actuator marks a major milestone for Diag-Nose - a testament to the team’s dedication, focus, and sacrifice.

Now, following graduation from Perth Biodesign and a 6 month relocation to Melbourne, Victoria just to participate, CEO Eldin Rostom has helped the company to receive it’s biggest pre-seed round yet.

And this comes hot on the heels of being a finalist in Medtech’s Got Talent.

Safe to say, Diag-Nose is on fire.

‍

MedTech Actuator - turning MedTech dreams into commercial reality

MedTech Actuator isn’t just another program.

It has helped over 1,000 startups accelerate healthcare innovation, engaged more than 70 industry partners, and generated $6 billion in market value across its portfolio.

The program’s impact on the workforce is equally impressive, with over 5,000 clinicians and researchers trained to thrive in industry.

And now, Diag-Nose is part of this startup-scaling powerhouse.

Mic drop.

‍

The difference the program will make for the company both now and in the future

Eldin and the team will participate in a huge 15-month intensive program, which will see technology development combined with entrepreneurial skill-building.

Beyond the unbelievable $200,000 investment, the program offers a fast-track to the first major round of venture capital investment through partners Artesian Venture Capital. Additionally, we will gain access to an extraordinary new network of mentors, business coaches, and industry experts to support us in our efforts.

“Having access to the Medtech Actuator program is a fantastic opportunity – it really takes a village to be able to grow a start-up and the program brings the village to you by surrounding the companies with mentors, business coaches and expert suppliers with a demonstrated track record in MedTech. This will allow Diag-Nose to continue validating our market and developing our product as well as gain access to potential future investors.” said Eldin.

With this support, Diag-Nose is set to advance its mission of reducing unnecessary antibiotic use and improving patient outcomes across Australia and beyond.

Keep an eye out for our latest breakthrough and behind-the scenes updates by following us on LinkedIn!

‍

About Diag-Nose.io

Diag-Nose.io, founded in 2020, is a TechBio company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions.

Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies.

The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.

Learn more at Diag-Nose.io

About MedTech Actuator

Founded in 2018, MedTech Actuator is Asia Pacific’s leading MedTech commercialisation program, dedicated to transforming health-based startups into global companies that deliver real-world impact.

The initiative connects founders, researchers, and investors, accelerating innovations that improve lives while driving economic growth. At its core, MedTech Actuator focuses on building capability - not just knowledge - empowering entrepreneurs with the skills, networks, and confidence to bring human-centred solutions to market.

United by a passion for innovation with tangible human impact, MedTech Actuator nurtures the next generation of healthtech leaders and breakthrough medical technologies.

Learn more at MedTech Actuator

‍